You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


NICE rejects rare blood cancer treatment Poteligeo in final appraisal

The UK’s National Institute for Health and Care Excellence (NICE) has not recommended Kyowa Kirin’s Poteligeo for the treatment of adults living with rare blood cancers in its final appraisal document (FAD).